MUTTENZ, Switzerland--(BUSINESS WIRE)--ImVisioN Therapeutics AG., a biopharmaceutical company pioneering intralymphatic immunotherapy (ILIT™), announced today that it has enrolled the first patient for a Phase I clinical study of its lead product IVN201, an immunotherapeutic product for cat dander allergy. The Company also announced the closing of a Series A Financing round of CHF 4.6 M, allowing the clinical development of IVN201. The financing round was led by Aravis Venture Associates AG and involved the participation of the founding investor Nextech Venture and private individuals.
